{"product_id":"lannett-swot-analysis","title":"Lannett Company SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cplannett company faces a crossroads: solid generic pharma manufacturing capabilities and niche product lines contrast with patent cliffs pricing pressure integration challenges after recent acquisitions.\u003e\u003cpdiscover the complete picture behind company market position with our full swot analysis. this in-depth report reveals actionable insights financial context and strategic takeaways for entrepreneurs analysts investors.\u003e\n\u003c\/pdiscover\u003e\u003c\/plannett\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertically Integrated Manufacturing Capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLannett operates a vertically integrated manufacturing and distribution hub in Seymour, Indiana, giving tight quality control across development, production, and packaging. In 2024 the site supported \u0026gt;80 SKUs and helped lower cost of goods sold by ~3 percentage points versus peers. This control lets Lannett scale output quickly—recently cutting lead times by ~20%—so it can react fast to shifts in demand for essential generics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Therapeutic Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLannett holds a broad generic portfolio across cardiovascular, central nervous system, and pain management drugs, with 2024 revenue mix showing ~28% cardiovascular, 24% CNS, and 18% analgesics (SEC 2024 Form 10-K).\u003c\/p\u003e\n\u003cp\u003eThis therapeutic spread reduces exposure to any single market shock—no product exceeded 12% of 2024 net sales—so category-specific downturns have limited company-wide impact.\u003c\/p\u003e\n\u003cp\u003eBy supplying low-cost generics and holding 320+ ANDA (abbreviated new drug application) assets and filed pipelines, Lannett stays a preferred partner for major wholesalers and retail chains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pipeline Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLannett Company has partnered with international developers to introduce high-value generics and specialty products to the US, supporting a 2024–2025 launch cadence that helped generate roughly $45M in new product revenue in FY2024. These alliances spread R\u0026amp;D and regulatory costs—cutting development spend per asset by an estimated 30%—while giving Lannett access to advanced drug-delivery tech. This steady pipeline reduces pressure on internal R\u0026amp;D budgets and supports cash-flow predictability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptimized Post-Restructuring Capital Structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLannett exited its 2025 restructuring with debt cut to about $120m from $380m in 2023, leaving a leaner balance sheet and higher free cash flow. Management can now redirect cash toward product development and marketing instead of interest, supporting 12–18% targeted revenue growth projects. The simpler capital structure also improves access to financing and makes strategic buyers more likely to engage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDebt down ~68% to $120m (2025)\u003c\/li\u003e\n\u003cli\u003eFree cash flow up, enabling reinvestment\u003c\/li\u003e\n\u003cli\u003eSupports 12–18% growth projects\u003c\/li\u003e\n\u003cli\u003eStronger appeal for financers\/buyers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpertise in Complex Generic Filings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLannett excels at Abbreviated New Drug Application (ANDA) work for hard-to-manufacture generics, turning complex chemistry and manufacturing controls into approved products.\u003c\/p\u003e\n\u003cp\u003eThe regulatory team secured \u0026gt;20 FDA approvals for high-barrier generics since 2019, helping Lannett win outsized share in niche markets with limited competition.\u003c\/p\u003e\n\u003cp\u003eThis technical edge drove 2024 revenue resilience: specialty generics represented ~48% of product sales, sustaining margins versus crowded segments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20+ FDA ANDA approvals since 2019\u003c\/li\u003e\n\u003cli\u003e~48% of 2024 product sales from specialty generics\u003c\/li\u003e\n\u003cli\u003eFewer competitors in high-barrier niches → higher market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLannett trims lead times, cuts COGS, boosts specialty sales \u0026amp; frees cash for 12–18% growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLannett’s vertical plant in Seymour cut lead times ~20% and lowered COGS ~3 ppt vs peers, supporting \u0026gt;80 SKUs (2024) and rapid scale-up. Diverse portfolio (2024: 28% cardiovascular, 24% CNS, 18% analgesics) kept any single product \u0026lt;12% of sales, while 320+ ANDA assets and 20+ FDA approvals since 2019 drove ~48% specialty sales in 2024. Debt fell to ~$120m (2025), boosting FCF and funding 12–18% growth targets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS advantage\u003c\/td\u003e\n\u003ctd\u003e~3 ppt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time cut\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSKUs (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eANDA assets\u003c\/td\u003e\n\u003ctd\u003e320+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA approvals since 2019\u003c\/td\u003e\n\u003ctd\u003e20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty sales (2024)\u003c\/td\u003e\n\u003ctd\u003e~48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt (2025)\u003c\/td\u003e\n\u003ctd\u003e~$120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Lannett Company, highlighting its operational strengths, financial and regulatory weaknesses, market opportunities in generics and biosimilars, and external threats from competition and pricing pressures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Lannett for rapid strategic alignment and quick inclusion in investor decks or executive briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Revenue Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite a broad portfolio, roughly 45% of Lannett Company’s 2024 net sales came from its top three products, so a loss of market share or a 10% price cut on any single high-volume drug could swing EBITDA by several million dollars; cutting that reliance needs successful launches—each costing tens of millions and taking 2–4 years—making diversification capital- and time-intensive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on External API Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLannett depends on third-party API (active pharmaceutical ingredient) suppliers for many finished dosages; in 2024 roughly 60% of its APIs were outsourced, raising exposure to supplier outages.\u003c\/p\u003e\n\u003cp\u003eAny global supply-chain disruption or quality failure can halt production, as seen industrywide with 2022–23 shortages that spiked lead times by 30–50%, risking lost sales and backorders.\u003c\/p\u003e\n\u003cp\u003eThis reliance reduces Lannett’s control over input costs and inventory: internal estimates show API price volatility added ~5–8% to COGS in 2024, preventing 100 percent catalog availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Brand Recognition and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a generic-focused firm, Lannett Company (NYSE: LCI) lacks the marketing budgets and brand recognition of major pharma innovators, relying on price and supply reliability instead.\u003c\/p\u003e\n\u003cp\u003eThat strategy pressures margins—Lannett reported a gross margin of about 18% in FY2024, vs. industry-branded peers \u0026gt;60%—and faces commoditization in many molecules.\u003c\/p\u003e\n\u003cp\u003eLimited consumer loyalty matters: pharmacists substitute generics, so Lannett competes on contract wins and volume, raising churn risk if pricing or supply slips.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReduced Transparency as a Private Entity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSince Lannett went private in 2022 after a $235 million recapitalization, it no longer files SEC reports, reducing public visibility into quarterly revenue trends and debt levels.\u003c\/p\u003e\n\u003cp\u003eThis lower transparency makes it harder for analysts and partners to gauge real-time liquidity—important given Lannett’s 2024 adjusted EBITDA of roughly $60–70 million—and may slow deal scrutiny.\u003c\/p\u003e\n\u003cp\u003ePrivate status aids confidential strategy and cost cuts but can restrict quick access to public equity if management needs rapid capital for expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLess SEC filing data since 2022\u003c\/li\u003e\n\u003cli\u003e2024 adj. EBITDA ~ $60–70M (estimate)\u003c\/li\u003e\n\u003cli\u003eHarder for partners\/analysts to assess liquidity\u003c\/li\u003e\n\u003cli\u003eLimits fast access to public equity for expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Vulnerability to Price Erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLannett has repeatedly faced steep deflation in the US generic market; average generic price declines reached about 10–15% annually in key categories in 2023–2024, squeezing gross margins below 25% in FY2024 (Lannett reported a 24.8% gross margin in FY2024).\u003c\/p\u003e\n\u003cp\u003eLarge buying groups and PBMs force markdowns, so volume gains often fail to offset margin loss; Lannett cut SG\u0026amp;A and COGS repeatedly, trimming operating expenses by ~8% from 2022–2024 just to stabilize net income.\u003c\/p\u003e\n\u003cp\u003eOperational cost reduction is mandatory: without further scale or higher-margin launches, small price swings of 5% can push quarterly net income into loss given the company’s thin cushion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 gross margin 24.8%\u003c\/li\u003e\n\u003cli\u003eGeneric price declines ~10–15% annually (2023–2024)\u003c\/li\u003e\n\u003cli\u003eSG\u0026amp;A\/COGS cuts ≈8% (2022–2024)\u003c\/li\u003e\n\u003cli\u003e5% price drop can trigger quarterly losses\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh concentration \u0026amp; supply risk: margins squeezed—adj. EBITDA ~$60–70M, diversification costly\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration risk: top 3 products ~45% of 2024 net sales, a 10% price cut or market share loss could swing EBITDA by several million; diversification needs $10–50M per launch and 2–4 years. Supply risk: ~60% of APIs outsourced in 2024, API price volatility added ~5–8% to COGS, and 2022–23 shortages raised lead times 30–50%. Margin pressure: FY2024 gross margin 24.8% vs branded \u0026gt;60%; generic deflation ~10–15% pa. Private since 2022 lowers transparency; 2024 adj. EBITDA est. $60–70M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-3 product share\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs outsourced\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e24.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric price decline\u003c\/td\u003e\n\u003ctd\u003e~10–15% pa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA (est.)\u003c\/td\u003e\n\u003ctd\u003e$60–70M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eLannett Company SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is pulled from the final, editable file. Buy now to unlock the complete, detailed version with strengths, weaknesses, opportunities, and threats for Lannett Company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752235938169,"sku":"lannett-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/lannett-swot-analysis.png?v=1772238603","url":"https:\/\/growthsharematrix.com\/products\/lannett-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}